Cannabinoids are a promising method for pharmacological treatment of post-traumatic stress disorder (PTSD). Despite considerable research devoted to the effect of cannabinoid modulation on PTSD symptomology, there is not a currently agreed way by which the cannabinoid system should be targeted in humans. In this review, we present an overview of recent research identifying neurological pathways by which different cannabinoid-based treatments may exert their effects on PTSD symptomology. We evaluate the strengths and weaknesses of each of these different approaches, including recent challenges presented to favourable options such as fatty acid amide hydrolase (FAAH) inhibitors. This article makes the strengths and challenges of different potential cannabinoid treatments accessible to psychological researchers interested in cannabinoid therapeutics and aims to aid selection of appropriate tools for future clinical trials.
History
Publication title
Progress in Neuropsychopharmacology and Biological Psychiatry
Volume
93
Pagination
124-140
ISSN
0278-5846
Department/School
School of Psychological Sciences
Publisher
Elsevier
Place of publication
United States
Rights statement
Copyright 2019 Elsevier Inc.
Repository Status
Restricted
Socio-economic Objectives
Public health (excl. specific population health) not elsewhere classified